Skip to content

Comparison of the Efficacy of Acupuncture versus Flunarizine Hydrochloride in the Treatment of Chronic Migraine

Comparison of the Efficacy of Acupuncture versus Flunarizine Hydrochloride in the Treatment of Chronic Migraine

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025002442
Enrollment
Unknown
Registered
2025-12-10
Start date
2025-12-19
Completion date
Unknown
Last updated
2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic migraine

Interventions

Acupuncture group:Acupoints: Baihui, Sishuzong, Luegu, Sun, Fengchi, Yanglingquan, Waiguan. Except Baihui, all the above acupoints are taken on both sides. This prescription of acupoints is selected f

Sponsors

Shanghai General Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: 1. Meet the diagnostic criteria for chronic migraine in the 3rd edition of the International Classification of Headache Disorders (ICHD-3) by the International Headache Society's Headache Classification Committee. 2. Be aged 18 to 60, have received at least 6 years of education, and be right-handed. 3. Have headache days of 15 or more per month, with migraine attacks occurring at least 5 times per month for more than 3 consecutive months, among which at least 8 days have migraine characteristics, and the average VAS score is greater than 3. 4. Have a basically normal brain structure, no history of depression, cerebrovascular disease, Parkinson's disease or other extrapyramidal diseases, and no history of major diseases in other systems. 5. Have no obvious long-term chronic pain in other parts of the body, such as chronic low back pain or neck pain. 6. Have not received non-pharmacological treatments such as acupuncture in the past 4 weeks, and have not taken any drugs with preventive or therapeutic effects on migraines, such as beta-blockers, calcium channel blockers, antiepileptic drugs, antidepressants, and 5-HT receptor antagonists. 7. Have no contraindications for MRI testing. 8. Have signed the informed consent form and voluntarily participate in this trial.

Exclusion criteria

Exclusion criteria: 1. Headaches caused by organic diseases or of other types and locations; 2. Self-rating Anxiety Scale (SAS) score = 50 points; 3. Severe asymmetry in the head's anatomical structure or clear lesions detected in MRI scans; 4. Individuals who abuse alcohol or other addictive drugs; 5. Those who cannot cooperate in completing this study.

Design outcomes

Primary

MeasureTime frame
The average weekly frequency of migraine attacks for patients with chronic migraine ;

Secondary

MeasureTime frame
Measurement of headache impact scores ;The scores of the migraine-specific quality of life questionnaire (MSQ) ;The Hospital Anxiety and Depression Scale scores (HADS) ;The visual analogue scale (VAS) ;The Self-Rating Anxiety Scale scores (SAS) ;The self-rating depression scale scores (SDS) ;The changes in the frequency of migraine attacks ;The changes in the frequency of painkillers ;

Countries

China

Contacts

Public ContactYichao Chen

Shanghai General Hospital

1332824841@qq.com18810727105

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026